William J. Gedale
Chairman, Board of Managers
Mr. Gedale is a Senior Advisor and co-founder of NGN Capital, and has been in the investment business since 1965. Mr. Gedale joined NGN from Mount Everest Advisors, which he founded in 1996. He has served as an investment advisor to individuals and as a full time consultant to Warburg-Pincus Capital Management, the world's largest venture capital firm. In this capacity, he initiated the $140 million dollar financing of ZymoGenetics. From 1969 to 1995 Mr. Gedale, was associated with General American Investors, during his tenure he helped arrange the $350 million funding by Sandoz (Novartis) of the Scripps Research Institute and the $40 million funding of the Neuroscience Research Institute of La Jolla, California (of which he is a trustee).
John F. Manzello
President and Chief Executive Officer
Mr. Manzello was appointed CEO of Promosome in 2007, bringing nearly 20 years of executive and director level experience in the biopharmaceutical industry with a concentration on business development and strategic alliances for the introduction of novel technologies. Prior to joining Promosome, Mr. Manzello was at San Diego's Althea Technologies. While at Althea, Mr. Manzello initiated and directed business development efforts supporting late phase biopharmaceutical production. Prior to Althea, Mr. Manzello utilized his talents and gained significant industry experience as Director of Business Development at Cohesive Technologies, Director of Commercial Development at Genzyme Transgenics and Director of Biopharmaceutical Services at Primedica Corporation. Mr. Manzello remains an active member of several biotechnology industry organizations and also serves on the Board of Directors of Recopharma AB, a Stockholm based biotherapeutic company.
Vincent P. Mauro, Ph.D.
Senior Vice President and Chief Scientific Officer
Dr. Mauro is the Senior Vice President and Chief Scientific Officer at Promosome. Dr. Mauro investigates fundamental mechanisms of translation initiation. His studies provided the first demonstration of mRNA:rRNA basepairing as a translation initiation mechanism in eukaryotes, and the identification of cis-regulatory elements in mRNAs, which include TEEs. He and his colleagues demonstrated that powerful synthetic translational enhancers can be generated by linking together individual TEEs together. More recently, Dr. Mauro and his colleagues have developed selection methodologies to identify such elements in mammalian cells and in yeast.